Showing results (41-50 of 64) with videos related to
Sort By:
Pageof 7
Science Advances|February 9, 2022
Screening of ETO2-GLIS2-induced Super Enhancers identifies targetable cooperative dependencies in acute megakaryoblastic leukemiaSalima Benbarche, Cécile K Lopez, Eralda Salataj, et al.Cytometry. Part B, Clinical Cytometry|November 27, 2024
Prospective feasibility of a minimal BH3 profiling assay in acute myeloid leukemiaKim Pacchiardi, Victoire de Marcellus, Tony Huynh, et al.Leukemia Research|November 22, 2019
BET inhibitors impair leukemic stem cell function only in defined oncogenic subgroups of acute myeloid leukaemiasAline Massé, Louise Roulin, Justine Pasanisi, et al.Cancer Discovery|February 23, 2013
Targeting MYCN in neuroblastoma by BET bromodomain inhibitionAlexandre Puissant, Stacey M Frumm, Gabriela Alexe, et al.Biorxiv : the Preprint Server for Biology|March 10, 2025
Pathway Coessentiality Mapping Reveals Complex II is Required for de novo Purine Biosynthesis in Acute Myeloid LeukemiaAmy E Stewart, Derek K Zachman, Pol Castellano-Escuder, et al.Nature Medicine|February 14, 2017
The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemiaNina Fenouille, Christopher F Bassil, Issam Ben-Sahra, et al.Nature Genetics|March 24, 2020
Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancerKevin H Lin, Justine C Rutter, Abigail Xie, et al.The Journal of Experimental Medicine|June 22, 2016
Targeting MTHFD2 in acute myeloid leukemiaYana Pikman, Alexandre Puissant, Gabriela Alexe, et al.Nature Metabolism|December 5, 2025
Pathway coessentiality mapping reveals complex II is required for de novo purine biosynthesis in acute myeloid leukaemiaAmy E Stewart, Derek K Zachman, Pol Castellano-Escuder, et al.Blood Cancer Journal|June 24, 2022
A multiparametric niche-like drug screening platform in acute myeloid leukemiaReinaldo Dal Bello, Justine Pasanisi, Romane Joudinaud, et al.Pageof 7